A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 65-74

  Chow, Laura Q M ^a,d   Gustafson, Daniel L ^a   O'Bryant, Cindy L ^a   Gore, Lia ^a   Basche, Michele ^a   Holden, Scott N ^a   Morrow, Mark C ^a   Grolnic, Stacy ^a   Creese, Brian R ^b   Roberts, Kaye L ^b   Davis, Kat ^b   Addison, Russell ^c   Eckhardt, S Gail ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Progen Pharmaceuticals Limited   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Advanced malignancies; Angiogenesis; Clinical trial; Docetaxel; Heparanase inhibitor; PI 88

Indexed keywords

DEXAMETHASONE; DOCETAXEL; FIBROBLAST GROWTH FACTOR 2; PI 88; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE CONTUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN TOXICITY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FIBROBLAST GROWTH FACTOR 2; GASTROINTESTINAL DISEASES; GLUCURONIDASE; HEPARIN; HUMANS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; OLIGOSACCHARIDES; PARTIAL THROMBOPLASTIN TIME; PLATELET FACTOR 4; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53149138189     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0712-z     Document Type: Article

References (55)

1. J Amiral F Bridey M Dreyfus AM Vissoc E Fressinaud M Wolf D Meyer 1992 Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia Thromb Haemost 68 95 96
2. Anderson RL, Lelekakis M, Lowen D et al (1998) Inhibition of lung metastasis from a breast carcinoma using PI88, a heparanase inhibitor. (abstr). Proc Metastatic Res Soc
3. SD Baker M Zhao CK Lee J Verweij Y Zabelina JR Brahmer AC Wolff A Sparreboom MA Carducci 2004 Comparative pharmacokinetics of weekly and every-three-weeks docetaxel Clin Cancer Res 10 1976 1983
4. MA Bareschino F Morgillo F Ciardiello 2007 Combination of standard chemotherapy and targeted agents J Thorac Oncol 2 S19 S23
5. M Basche DL Gustafson SN Holden CL O'Bryant L Gore S Witta MK Schultz M Morrow A Levin BR Creese M Kangas K Roberts T Nguyen K Davis RS Addison JC Moore SG Eckhardt 2006 A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors Clin Cancer Res 12 5471 5480
6. CP Belani 2005 Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel Lung Cancer 50 Suppl 2 S3 S8
7. A Berkenblit MV Seiden UA Matulonis RT Penson CN Krasner M Roche L Mezzetti T Atkinson SA Cannistra 2004 A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer Gynecol Oncol 95 624 631
8. R Bruno D Hille A Riva N Vivier WW ten Bokkel Huinnink AT van Oosterom SB Kaye J Verweij FV Fossella V Valero JR Rigas AD Seidman B Chevallier P Fumoleau HA Burris PM Ravdin LB Sheiner 1998 Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 187 196
9. HA Charleson RR Bailey A Stewart 1980 Quick prediction of creatinine clearance without the necessity of urine collection N Z Med J 92 425 426
10. BH Chong 1995 Heparin-induced thrombocytopenia Br J Haematol 89 431 439
11. BH Chong M Eisbacher 1998 Pathophysiology and laboratory testing of heparin-induced thrombocytopenia Semin Hematol 35 3 8 discussion 35-36
12. DE Cohn S Valmadre KE Resnick LA Eaton LJ Copeland JM Fowler 2006 Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecol Oncol 102 134 139
13. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 4368 4380
14. SG Eckhardt HA Burris JR Eckardt G Weiss G Rodriguez M Rothenberg D Rinaldi R Barrington JG Kuhn K Masuo K Sudo R Atsumi T Oguma L Higashi S Fields L Smetzer DD Von Hoff 1996 A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium Ann Oncol 7 491 496
15. E Edovitsky M Elkin E Zcharia T Peretz I Vlodavsky 2004 Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis J Natl Cancer Inst 96 1219 1230
16. ON El-Assal A Yamanoi T Ono H Kohno N Nagasue 2001 The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma Clin Cancer Res 7 1299 1305
17. J Folkman 1995 Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N Engl J Med 333 1757 1763
18. K Ganjoo 2007 Antiangiogenesis: a new approach to the treatment of lymphoma Leuk Lymphoma 48 454 455
19. R Gervais A Ducolone JL Breton D Braun B Lebeau F Vaylet D Debieuvre JL Pujol J Tredaniel P Clouet E Quoix 2005 Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann Oncol 16 90 96
20. DL Gustafson ME Long JA Zirrolli MW Duncan SN Holden AS Pierson SG Eckhardt 2003 Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay Cancer Chemother Pharmacol 52 159 166
21. JD Hainsworth 2004 Practical aspects of weekly docetaxel administration schedules Oncologist 9 538 545
22. JD Hainsworth HA Burris III DA Yardley JE Bradof M Grimaldi LA Kalman T Sullivan M Baker JB Erland FA Greco 2001 Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial J Clin Oncol 19 3500 3505
23. A Hurria MT Fleming SD Baker WK Kelly K Cutchall K Panageas J Caravelli H Yeung MG Kris J Gomez VA Miller G D'Andrea HI Scher L Norton C Hudis 2006 Pharmacokinetics and toxicity of weekly docetaxel in older patients Clin Cancer Res 12 6100 6105
24. Y Ji Y Li B Nebiyou Bekele 2007 Dose-finding in phase I clinical trials based on toxicity probability intervals Clin Trials 4 235 244
25. A Koliopanos H Friess J Kleeff X Shi Q Liao I Pecker I Vlodavsky A Zimmermann MW Buchler 2001 Heparanase expression in primary and metastatic pancreatic cancer Cancer Res 61 4655 4659
26. RC Lilenbaum MA Schwartz L Seigel F Belette A Blaustein FN Wittlin E Davila 2001 Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma Cancer 92 2158 2163
27. T Lynch Jr E Kim 2005 Optimizing chemotherapy and targeted agent combinations in NSCLC Lung Cancer 50 S2 S25 S32
28. U Mey M Gorschluter C Ziske R Kleinschmidt A Glasmacher IG Schmidt-Wolf 2003 Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial Anticancer Drugs 14 233 238
29. HQ Miao H Liu E Navarro P Kussie Z Zhu 2006 Development of heparanase inhibitors for anti-cancer therapy Curr Med Chem 13 2101 2111
30. S Mikami K Ohashi K Katsube T Nemoto M Nakajima Y Okada 2004 Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas Pathol Int 54 556 563
31. S Mikami K Ohashi Y Usui T Nemoto K Katsube M Yanagishita M Nakajima K Nakamura M Koike 2001 Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas Jpn J Cancer Res 92 1062 1073
32. JA Nagy E Vasile D Feng C Sundberg LF Brown MJ Detmar JA Lawitts L Benjamin X Tan EJ Manseau AM Dvorak HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis J Exp Med 196 1497 1506
33. RL Panares AA Garcia 2007 Bevacizumab in the management of solid tumors Expert Rev Anticancer Ther 7 433 445
34. CR Parish C Freeman KJ Brown DJ Francis WB Cowden 1999 Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity Cancer Res 59 3433 3441
35. Pavlakis N, Parish C, Freeman C et al (2000) The heparanase inhibitor PI-88 reduces tumor growth in two rat mammary adenocarcinoma models, demonstrating schedule dependency and possible synergy with cisplatin (abstr). Proc Am Assoc Cancer Res
36. Progen, Industries, Ltd (2004) Investigator's brochure on PI-88. Progen Industries Ltd, Darra, Queensland, Australia. July 2004. (unpublished) Progen Industries Ltd
37. B Ramaswamy AD Elias NT Kelbick A Dodley M Morrow M Hauger J Allen C Rhoades K Kendra HX Chen SG Eckhardt CL Shapiro 2006 Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clin Cancer Res 12 3124 3129
38. B Ramaswamy CL Shapiro 2003 Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer Clin Breast Cancer 4 292 294
39. G Ranieri R Patruno E Ruggieri S Montemurro P Valerio D Ribatti 2006 Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 13 1845 1857
40. M Robertshaw KN Lai R Swaminathan 1989 Prediction of creatinine clearance from plasma creatinine: comparison of five formulae Br J Clin Pharmacol 28 275 280
41. L Rosen 2000 Antiangiogenic strategies and agents in clinical trials Oncologist 5 Suppl 1 20 27
42. MA Rosenthal D Rischin G McArthur K Ribbons B Chong J Fareed G Toner MD Green RL Basser 2002 Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia Ann Oncol 13 770 776
43. W Schuette S Nagel T Blankenburg C Lautenschlaeger K Hans EW Schmidt I Dittrich H Schweisfurth LF von Weikersthal A Raghavachar A Reissig M Serke 2005 Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel J Clin Oncol 23 8389 8395
44. D Sheridan C Carter JG Kelton 1986 A diagnostic test for heparin-induced thrombocytopenia Blood 67 27 30
45. PJ Shteper E Zcharia Y Ashhab T Peretz I Vlodavsky D Ben-Yehuda 2003 Role of promoter methylation in regulation of the mammalian heparanase gene Oncogene 22 7737 7749
46. S Simizu K Ishida MK Wierzba TA Sato H Osada 2003 Expression of heparanase in human tumor cell lines and human head and neck tumors Cancer Lett 193 83 89
47. J Tabernero MA Climent A Lluch J Albanell JB Vermorken A Barnadas A Anton C Laurent JI Mayordomo N Estaun I Losa V Guillem J Garcia-Conde JL Tisaire J Baselga 2004 A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann Oncol 15 1358 1365
48. J Taipale J Keski-Oja 1997 Growth factors in the extracellular matrix Faseb J 11 51 59
49. P Therasse 2002 Measuring the clinical response. What does it mean? Eur J Cancer 38 1817 1823
50. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
51. J Turnbull A Powell S Guimond 2001 Heparan sulfate: decoding a dynamic multifunctional cell regulator Trends Cell Biol 11 75 82
52. VW van Hinsbergh A Collen P Koolwijk 1999 Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors Ann Oncol 10 Suppl 4 60 63
53. X Xu G Rao RM Quiros AW Kim HQ Miao GJ Brunn JL Platt P Gattuso RA Prinz 2007 In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation J Biol Chem 282 2363 2373
54. A Yayon M Klagsbrun JD Esko P Leder DM Ornitz 1991 Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor Cell 64 841 848
55. W Zhang M Gordon HJ Lenz 2006 Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies Ann Med 38 545 551